Inflarx NV logo

IFRX - Inflarx NV News Story

$3.77 0.1  1.9%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £116.4m
Enterprise Value £46.6m
Revenue £n/a
Position in Universe 4743rd / 6841

InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference

Thu 7th January, 2021 12:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210107:nGNX8Zl78r&default-theme=true


JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX),
a clinical-stage biopharmaceutical company developing anti-inflammatory
therapeutics by targeting the complement system, will present virtually at the
39(th) Annual J.P. Morgan Healthcare Conference being held January 11-14,
2021.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will
give a corporate presentation on Thursday, January 14(th) at 7:30 am EST (1:30
pm CET). A live audio w
(https://www.globenewswire.com/Tracker?data=9V26cVfXBQY1UbLIzBwqkQOThAN_04gTCtlSMTANihwow_VThHySM_DwJXIUKjoilV4n6rzXwA-y-aqCThR8NRP6dr07--CB1B-75b_sRnqOSKVsC2UYW8N2a8VOz_xP)e
(https://www.globenewswire.com/Tracker?data=DOixwMgJ8Tn_31ShbeZbXK3swWbwuoGEwECp6ELLwUK14g8LqPLRePQhtWDZVM5sN50LNCaJb9ihFi_a0g7JXXgjN2_l9pxC7MMnEAhbUbeWVIQoDHfL6J4yZJAlObdy)bcast
(https://www.globenewswire.com/Tracker?data=V2pP47sZ1KgQZKvmIR0E5umhVfr63WFbENRYx0GeJthl2pVJUWmaOUNMx8_RD-lMydhvW38i4ekvkVoju9cDlFVi_KYtaNdCU90NWSKoCjNNL1RegbZKV2nvYHy9tehF)
of the presentation will be provided on the InflaRx website in the Investors
section under Events & Presentations. A webcast replay will be archived for
approximately 30 days.

Also, an on
(https://www.globenewswire.com/Tracker?data=AvWwKWZlcJTUbw_BHjLNhWn0oFNzmZMv9trJu7RGaaZm3f58-rkhxsWIyFqLcFtTlByOteN7I6RvPv67p4dUGYTpef51C_2tQbeDy5lZiZ5Mf11pwH2FswtF9ga7qAPS)-
(https://www.globenewswire.com/Tracker?data=fzuP5yBy8MzrIJ1BTCSDkFf38Z_S2nrOXbYp51XKkbkZJjLqJj0CbtS669yldsRlsSom_qiI7SWQ-NIa1zFdHcTrUW5x9QPsp21IdMJpTGzCN8SNP7qmoSTSoqhBGCUq)de
(https://www.globenewswire.com/Tracker?data=Plf6yKkwOhXzmy7d3AdP70dWdUAPYy-0SukL4kEXp13thnnAzBaS7J7SX7nqPQx6sGkp06PR8xB3PiRkvC-lA5WJeINDew3qcCm-gT-lTAzFZqRgH8mn8StSbbRQop9H)m
(https://www.globenewswire.com/Tracker?data=lbeib4pT1huPoeDDPFJM57apmDp8HGn0Jn25X5SONngYP_roN6aLYnmfDnylN2MgnjiJIQcpzy-5ec_AAWL8UuuoTDp3jac_L_gR4WCrIUa_X-EPw4IXbYEkaDCv8JvR)and
webcast
(https://www.globenewswire.com/Tracker?data=puxFowrnySrNavjm4pcz0psdqBwIr_nnb_jgHH0mR3jiNDKsc8gd1sb0D0QhTisPzbn_OGi6fKSobeQ_O-heI5k5tG_3sR2zGwexwAk14VNuKYpV1QKHu41vcidcMTYQafnVM7Tb4yqjGTyb8b5n9w==)
of a corporate presentation from the H.C. Wainwright Virtual BioConnect
Conference will be available starting Monday, January 11(th) at 6:00 am EST
(12:00 pm CET) on the InflaRx website in the Investors section under Events &
Presentations.

About InflaRx N.V.: 
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused
on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a
powerful inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded in 2007,
and the group has offices and subsidiaries in Jena and Munich, Germany, as
well as Ann Arbor, MI, USA. For further information please visit
www.inflarx.com.

Contacts:

InflaRx N.V.

Jordan Zwick – Chief Strategy Officer
Email: jordan.zwick@inflarx.de
Tel: +1 917-338-6523

MC Services AG

Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things, our ongoing
and planned pre-clinical development and clinical trials; the impact of the
COVID-19 pandemic on the Company; the timing and our ability to commence and
conduct clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain positive
guidance from regulators, and obtain and maintain regulatory approvals for our
product candidates; our intellectual property position; our ability to develop
commercial functions; expectations regarding clinical trial data; our results
of operations, cash needs, financial condition, liquidity, prospects, future
transactions, growth and strategies; the industry in which we operate; the
trends that may affect the industry or us and the risks, uncertainties and
other factors described under the heading “Risk Factors” in InflaRx’s
periodic filings with the Securities and Exchange Commission. These statements
speak only as of the date of this press release and involve known and unknown
risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and other
factors, you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as
required by law.

(https://www.globenewswire.com/NewsRoom/AttachmentNg/38d5f700-4678-4aa4-a293-4118e2b21998)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.